Business

Announcement on Acquisition of Drug Registration Certificate for New Indication of Acute Ischemic Cerebral Stroke of the Wholly-owned Subsidiary's Reocmbinant Human Prourokinase for Injection

Announcement on Acquisition of Drug Registration Certificate for New Indication of Acute Ischemic Cerebral Stroke of the Wholly-owned Subsidiary's Reocmbinant Human Prourokinase for Injection

articleTasly Pharmaceutical Group Co. Ltd. Class ASeptember 22, 20254/news/announcement-on-acquisition-of-drug-registration-certificate-for-new-indication-of-acute-ischemic-cerebral-stroke-of-the-wholly-owned-subsidiarys-reocmbinant-human-prourokinase-for-injection
Announcement on Acquisition of Drug Registration Certificate for New Indication of Acute Ischemic Cerebral Stroke of the Wholly-owned Subsidiary's Reocmbinant Human Prourokinase for Injection

About this update from Tasly Pharmaceutical Group Co. Ltd. Class A

Announcement on Acquisition of Drug Registration Certificate for New Indication of Acute Ischemic Cerebral Stroke of the Wholly-owned Subsidiary's Reocmbinant Human Prourokinase for InjectionThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Tasly Pharmaceutical Group Co. Ltd. Class A